ReachMD CME

CME credits: 0.25 Valid until: 14-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/no-patient-with-ckd-left-behind-new-horizons-in-patients-with-ckd-regardless-of-diabetes-status/49260/ A growing body of evidence presented at ERA 2026 is reshaping the conversation around chronic kidney disease management, regardless of diabetes status. In this expert interview, Dr. Katherine Tuttle and Dr. Brendon Neuen examine emerging data on nonsteroidal mineralocorticoid receptor antagonists and discuss how recent findings may expand treatment considerations for patients with chronic kidney disease (CKD), including those without diabetes. Through expert analysis of key studies and a patient perspective, the faculty explore the evolving cardiorenal landscape, practical implications for clinical practice, and opportunities to address persistent unmet needs across the CKD spectrum.=

CME credits: 1.00 Valid until: 30-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/gaps-global-implementation-lipid-guidelines/54672/ A new modular CME-accredited program designed to support clinicians in translating evolving lipid guidelines into everyday practice. Delivered as a 60-minute webcast, divided into chapters for convenience, it integrates U.S. and international perspectives and focuses on equitable cardiovascular care. The course highlights women-specific cardiovascular risk modifiers, including reproductive and hormonal factors that are often under-recognized in risk assessment. It also emphasizes practical, multidisciplinary approaches to improving lipid management outcomes across diverse health systems. =

CME credits: 0.50 Valid until: 23-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/reimagining-alzheimers-care-the-advent-of-subcutaneous-administration-of-anti-amyloid-therapy/39878/ In this activity, Dr. Alireza Atri and Dr. Scott Turner discuss the evolving role of subcutaneous anti-amyloid monoclonal antibody therapy in early Alzheimer disease. The conversation compares intravenous and subcutaneous administration and focuses on maintenance dosing after 18 months of IV therapy, practical implications for patients and care partners, and the potential impact on infusion-center burden and treatment access. Dr. Dani Cabral then speaks with a patient living with Alzheimer's disease, who shares his perspective on using the subcutaneous formulation in the broader context of disease-modifying treatment and long-term management.=

CME credits: 0.25 Valid until: 23-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/translating-evidence-into-action-nonsteroidal-mras-in-patients-with-hf/49259/ In this panel discussion from the ESC Heart Failure Congress 2026, Drs. Muthu Vaduganathan, Michael Böhm, and Koichiro Kinugawa discuss the role of nonsteroidal MRAs in patients with HFmrEF and HFpEF. Using a clinical case, the faculty review evolving recommendations supporting finerenone as part of guideline-directed medical therapy, along with evidence from FINEARTS-HF and related analyses. The discussion highlights considerations for early initiation, use in combination with SGLT2 inhibitors, patient selection, dosing and monitoring, and management of potassium and renal function changes in clinical practice.=

CME credits: 0.25 Valid until: 18-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/engaging-adult-patients-with-c3gn-shared-decision-making-at-the-crossroads-of-complement-targeted-therapy/54145/ In this Patient-Clinician Connection, Dr. Sayna Norouzi discusses shared decision-making approaches for adult patients with C3 glomerulonephritis (C3GN) receiving complement-targeted therapies. Through a clinical patient vignette, Dr. Norouzi demonstrates patient-centered communication techniques for discussing mechanisms, treatment considerations, and long-term kidney preservation goals in clear, accessible language. Dr. Norouzi reviews key differences among treatment approaches, including mechanism of action, proteinuria reduction, kidney function stabilization, monitoring requirements, route of administration, adherence considerations, and infection risk. The activity also highlights the importance of vaccination review, ongoing monitoring, and aligning treatment decisions with patient priorities and lifestyle factors to support collaborative care planning and patient engagement in C3GN management.=

CME credits: 1.00 Valid until: 16-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/De-Novo-mHSPC-Recognizing-the-Patients-Who-Need-More/57195/ This activity explores current approaches to treatment intensification in metastatic hormone-sensitive prostate cancer (mHSPC), including androgen deprivation therapy (ADT), androgen receptor pathway inhibitors (ARPIs), chemotherapy, and emerging targeted therapies. Drs. Scott Tagawa and Mary-Ellen Taplin discuss how disease volume, metastatic distribution, comorbidities, and patient goals inform individualized treatment selection. The program reviews key clinical trial evidence, the evolving role of germline and somatic testing, PTEN loss and AKT pathway targeting, and multidisciplinary strategies to manage adverse events and support quality of life during therapy. *Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

CME credits: 1.00 Valid until: 16-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/ADT-Intensification-The-Evidence-You-Cant-Afford-to-Miss/57196/ This activity explores current approaches to treatment intensification in metastatic hormone-sensitive prostate cancer (mHSPC), including androgen deprivation therapy (ADT), androgen receptor pathway inhibitors (ARPIs), chemotherapy, and emerging targeted therapies. Drs. Scott Tagawa and Mary-Ellen Taplin discuss how disease volume, metastatic distribution, comorbidities, and patient goals inform individualized treatment selection. The program reviews key clinical trial evidence, the evolving role of germline and somatic testing, PTEN loss and AKT pathway targeting, and multidisciplinary strategies to manage adverse events and support quality of life during therapy. *Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

CME credits: 1.00 Valid until: 16-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/Case-Implementing-ADT-Intensification-in-mHSPC/57197/ This activity explores current approaches to treatment intensification in metastatic hormone-sensitive prostate cancer (mHSPC), including androgen deprivation therapy (ADT), androgen receptor pathway inhibitors (ARPIs), chemotherapy, and emerging targeted therapies. Drs. Scott Tagawa and Mary-Ellen Taplin discuss how disease volume, metastatic distribution, comorbidities, and patient goals inform individualized treatment selection. The program reviews key clinical trial evidence, the evolving role of germline and somatic testing, PTEN loss and AKT pathway targeting, and multidisciplinary strategies to manage adverse events and support quality of life during therapy. *Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

CME credits: 1.00 Valid until: 16-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/Winning-the-Battle-Against-Side-Effects-Adverse-Event-Management-in-HSPC/57198/ This activity explores current approaches to treatment intensification in metastatic hormone-sensitive prostate cancer (mHSPC), including androgen deprivation therapy (ADT), androgen receptor pathway inhibitors (ARPIs), chemotherapy, and emerging targeted therapies. Drs. Scott Tagawa and Mary-Ellen Taplin discuss how disease volume, metastatic distribution, comorbidities, and patient goals inform individualized treatment selection. The program reviews key clinical trial evidence, the evolving role of germline and somatic testing, PTEN loss and AKT pathway targeting, and multidisciplinary strategies to manage adverse events and support quality of life during therapy. *Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

CME credits: 1.00 Valid until: 16-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/Molecular-Profiling-in-mHSPC-Informing-Treatment-Selection/57199/ This activity explores current approaches to treatment intensification in metastatic hormone-sensitive prostate cancer (mHSPC), including androgen deprivation therapy (ADT), androgen receptor pathway inhibitors (ARPIs), chemotherapy, and emerging targeted therapies. Drs. Scott Tagawa and Mary-Ellen Taplin discuss how disease volume, metastatic distribution, comorbidities, and patient goals inform individualized treatment selection. The program reviews key clinical trial evidence, the evolving role of germline and somatic testing, PTEN loss and AKT pathway targeting, and multidisciplinary strategies to manage adverse events and support quality of life during therapy. *Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

CME credits: 1.00 Valid until: 16-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/Targeting-PTEN-Why-It-Matters/57200/ This activity explores current approaches to treatment intensification in metastatic hormone-sensitive prostate cancer (mHSPC), including androgen deprivation therapy (ADT), androgen receptor pathway inhibitors (ARPIs), chemotherapy, and emerging targeted therapies. Drs. Scott Tagawa and Mary-Ellen Taplin discuss how disease volume, metastatic distribution, comorbidities, and patient goals inform individualized treatment selection. The program reviews key clinical trial evidence, the evolving role of germline and somatic testing, PTEN loss and AKT pathway targeting, and multidisciplinary strategies to manage adverse events and support quality of life during therapy. *Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

CME credits: 0.75 Valid until: 16-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/unblocking-clinical-inertia-the-cmi-era-in-ohcm-care/56382/ Did you miss our symposium at ESC HF 2026? It's not too late! This CME-accredited broadcast replay focuses on improving the diagnosis and management of obstructive hypertrophic cardiomyopathy (oHCM). Learn how to distinguish oHCM from heart failure and how cardiac myosin inhibitors can optimize patient outcomes. Join us and gain valuable tips on applying these insights in practice.For more information please visit the Heart Failure Congress 2026 website.=

CME credits: 0.50 Valid until: 15-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/ibd-masterclass-choosing-the-right-ibd-therapy-a-patient-clinician-connection/54374/ Join Drs. Odufalu and Iroku for this Patient-Clinician Connection, a case-based activity focused on optimizing management of inflammatory bowel disease. Through real-world patient dialogues in Crohn's disease and ulcerative colitis, this program examines clinical and deep remission, along with treat-to-target principles to guide care. Faculty discuss decision-making around biologic de-escalation, as well as identification of mechanistic failure using therapeutic drug monitoring. The activity also reviews guideline-informed therapy selection across mechanisms, incorporating patient-specific factors such as extraintestinal manifestations, reproductive considerations, and treatment preferences to support individualized, steroid-free remission strategies.=

CME credits: 0.25 Valid until: 15-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/simple-diagnostic-steps-that-change-td-outcomes-increase-quality-of-life/54716/ This Podcast Plus discussion outlines standardized approaches to identifying and managing tardive dyskinesia. It reviews routine screening practices, use of tools such as AIMS, and key symptoms and timing in at-risk patients. The program also addresses post-diagnosis steps, including patient education, treatment considerations, and coordination of multidisciplinary care to support consistent follow-up and clinical management.=

CME credits: 0.75 Valid until: 08-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/leadoff-hitter-spotting-high-risk-players/56435/ This MinuteCE program brings a practical, team-based approach to improving atherosclerotic cardiovascular disease (ASCVD) prevention. Featuring expert multidisciplinary insights from Joseph Englert, MD, and Matt Malachowski, PharmD, this series focuses on identifying high-risk and underserved patients, advancing LDL-C–centered treatment strategies, and sustaining long-term secondary prevention.Across the program, faculty highlight guideline-aligned approaches to risk assessment, treatment intensification—including combination lipid-lowering therapy—and ongoing lipid monitoring. Emphasis is placed on coordinated, systems-based care strategies that support adherence, streamline workflows, and improve patient outcomes to help clinicians close care gaps one inning at a time.

CME credits: 0.75 Valid until: 08-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/swing-for-the-fences-ldl-c-as-the-power-hitter/56437/ This MinuteCE program brings a practical, team-based approach to improving atherosclerotic cardiovascular disease (ASCVD) prevention. Featuring expert multidisciplinary insights from Joseph Englert, MD, and Matt Malachowski, PharmD, this series focuses on identifying high-risk and underserved patients, advancing LDL-C–centered treatment strategies, and sustaining long-term secondary prevention.Across the program, faculty highlight guideline-aligned approaches to risk assessment, treatment intensification—including combination lipid-lowering therapy—and ongoing lipid monitoring. Emphasis is placed on coordinated, systems-based care strategies that support adherence, streamline workflows, and improve patient outcomes to help clinicians close care gaps one inning at a time.

CME credits: 0.75 Valid until: 08-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/small-ball-wins-games-combination-therapy-for-goal-attainment/56438/ This MinuteCE program brings a practical, team-based approach to improving atherosclerotic cardiovascular disease (ASCVD) prevention. Featuring expert multidisciplinary insights from Joseph Englert, MD, and Matt Malachowski, PharmD, this series focuses on identifying high-risk and underserved patients, advancing LDL-C–centered treatment strategies, and sustaining long-term secondary prevention.Across the program, faculty highlight guideline-aligned approaches to risk assessment, treatment intensification—including combination lipid-lowering therapy—and ongoing lipid monitoring. Emphasis is placed on coordinated, systems-based care strategies that support adherence, streamline workflows, and improve patient outcomes to help clinicians close care gaps one inning at a time.

CME credits: 0.75 Valid until: 08-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/extra-innings-sustaining-victory-beyond-the-first-game/56439/ This MinuteCE program brings a practical, team-based approach to improving atherosclerotic cardiovascular disease (ASCVD) prevention. Featuring expert multidisciplinary insights from Joseph Englert, MD, and Matt Malachowski, PharmD, this series focuses on identifying high-risk and underserved patients, advancing LDL-C–centered treatment strategies, and sustaining long-term secondary prevention.Across the program, faculty highlight guideline-aligned approaches to risk assessment, treatment intensification—including combination lipid-lowering therapy—and ongoing lipid monitoring. Emphasis is placed on coordinated, systems-based care strategies that support adherence, streamline workflows, and improve patient outcomes to help clinicians close care gaps one inning at a time.

CME credits: 0.75 Valid until: 08-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/turning-the-double-play-comprehensive-secondary-prevention/56440/ This MinuteCE program brings a practical, team-based approach to improving atherosclerotic cardiovascular disease (ASCVD) prevention. Featuring expert multidisciplinary insights from Joseph Englert, MD, and Matt Malachowski, PharmD, this series focuses on identifying high-risk and underserved patients, advancing LDL-C–centered treatment strategies, and sustaining long-term secondary prevention.Across the program, faculty highlight guideline-aligned approaches to risk assessment, treatment intensification—including combination lipid-lowering therapy—and ongoing lipid monitoring. Emphasis is placed on coordinated, systems-based care strategies that support adherence, streamline workflows, and improve patient outcomes to help clinicians close care gaps one inning at a time.

CME credits: 0.75 Valid until: 08-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/crossing-home-plate-building-a-winning-team-culture/56441/ This MinuteCE program brings a practical, team-based approach to improving atherosclerotic cardiovascular disease (ASCVD) prevention. Featuring expert multidisciplinary insights from Joseph Englert, MD, and Matt Malachowski, PharmD, this series focuses on identifying high-risk and underserved patients, advancing LDL-C–centered treatment strategies, and sustaining long-term secondary prevention.Across the program, faculty highlight guideline-aligned approaches to risk assessment, treatment intensification—including combination lipid-lowering therapy—and ongoing lipid monitoring. Emphasis is placed on coordinated, systems-based care strategies that support adherence, streamline workflows, and improve patient outcomes to help clinicians close care gaps one inning at a time.

CME credits: 0.50 Valid until: 23-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/elevate-elacestrant-plus-capivasertib-in-advanced-breast-cancer/57227/ Oral selective estrogen receptor degraders (SERDs) are rapidly reshaping the treatment landscape in breast cancer, offering targeted treatment approaches that have demonstrated improvements in progression-free survival and expanded options for patients with ER-positive/HER2-negative disease. Recent ASCO data highlighted the growing role of oral SERDs in optimizing treatment sequencing, addressing ESR1 mutations, and supporting personalized care across early-stage and metastatic settings. These therapies may also facilitate more convenient, patient-centered management while advancing precision medicine approaches in breast cancer care. *Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 0.50.

CME credits: 0.50 Valid until: 23-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/ongoing-trials-in-oral-targeted-strategies-in-breast-cancer/57228/ Oral selective estrogen receptor degraders (SERDs) are rapidly reshaping the treatment landscape in breast cancer, offering targeted treatment approaches that have demonstrated improvements in progression-free survival and expanded options for patients with ER-positive/HER2-negative disease. Recent ASCO data highlighted the growing role of oral SERDs in optimizing treatment sequencing, addressing ESR1 mutations, and supporting personalized care across early-stage and metastatic settings. These therapies may also facilitate more convenient, patient-centered management while advancing precision medicine approaches in breast cancer care. *Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 0.50.

CME credits: 0.50 Valid until: 23-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/serena-6-acting-on-esr1-mutations-in-advanced-breast-cancer/57229/ Oral selective estrogen receptor degraders (SERDs) are rapidly reshaping the treatment landscape in breast cancer, offering targeted treatment approaches that have demonstrated improvements in progression-free survival and expanded options for patients with ER-positive/HER2-negative disease. Recent ASCO data highlighted the growing role of oral SERDs in optimizing treatment sequencing, addressing ESR1 mutations, and supporting personalized care across early-stage and metastatic settings. These therapies may also facilitate more convenient, patient-centered management while advancing precision medicine approaches in breast cancer care. *Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 0.50.

CME credits: 1.00 Valid until: 04-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/a-q-challengetm-replay-advancing-precision-diagnosis-and-treatment-strategies-in-acromegaly/49278/ This broadcast replay from AACE 2026 features an interactive, case-based Q-Challenge format focused on acromegaly. Participants engage with clinical scenarios designed to assess and reinforce diagnostic evaluation and treatment decision-making. The activity highlights key considerations in identifying acromegaly, interpreting clinical findings, and selecting appropriate management strategies based on patient presentation. Through guided questions and expert-informed discussion, learners gain insight into the real-world application of evidence-based approaches.=

CME credits: 0.25 Valid until: 03-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/first-5-minutes-empowering-shared-decisions-in-lung-cancer-screening/50985/ This episode focuses on improving lung cancer screening and early detection by helping primary care providers recognize eligible and high-risk patients, apply current screening guidelines, and engage patients in clear shared decision-making conversations. Speakers will explore why many patients who qualify for low-dose CT scan screening are still not screened. Learn practice strategies to help close preventable gaps in care, including identifying risk during routine visits, addressing patient concerns, ordering appropriate screening, and ensuring follow-up for findings such as pulmonary nodules. =

CME credits: 1.00 Valid until: 02-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/seeing-the-invisible-radiologic-precision-to-enable-early-intervention-in-bronchiectasis/56384/ Bronchiectasis is a chronic, progressive respiratory disease that is characterized by accelerated lung function decline and impaired quality of life, yet it remains substantially under recognized and underdiagnosed in routine practice. High-resolution computed tomography is the cornerstone of diagnosis, but early and subtle radiologic manifestations are frequently overlooked or misattributed to aging, infection, or nonspecific small airway disease. Radiologists occupy a pivotal position as the earliest decision-makers in the bronchiectasis care pathway, so it is imperative that they can identify bronchiectasis accurately and early to ensure timely referral to specialized care for evidence-based therapy.=

CME credits: 0.25 Valid until: 01-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/chairpersons-perspective-reframing-first-line-and-subsequent-care-in-advanced-urothelial-carcinoma-clinical-implications-of-the-updated-nccn-guidelines/54396/ This 15-minute online CME activity reviews the clinical implications of the updated NCCN Guidelines for advanced urothelial carcinoma (aUC), with a focus on evolving first-line and subsequent treatment strategies. The program highlights the shift away from cisplatin eligibility as the primary determinant of frontline therapy selection and examines key clinical trial data that inform current practice. Participants will explore sequencing considerations following frontline therapy as well as the role of biomarker-directed therapies in later lines of care. The activity also emphasizes early recognition and management of treatment-related adverse events alongside strategies for dose modification and supportive care. Multidisciplinary coordination and shared decision-making are discussed as essential components of optimizing patient-centered care in aUC.=

CME credits: 0.25 Valid until: 01-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/chairpersons-perspective-her2-in-solid-tumors-from-pathology-to-personalized-treatment-plans/54582/ Dr. Kathleen Moore reviews the clinical significance of HER2 expression across diverse solid tumors and its role in guiding treatment decisions. She outlines HER2 testing methodologies, including immunohistochemistry (IHC), to identify patients with advanced solid tumors who may benefit from HER2-targeted antibody–drug conjugates (ADCs). Dr. Moore summarizes key data from trials such as DESTINY-PanTumor02, DESTINY-Lung01, and DESTINY-CRC02 that supported tumor-agnostic approval of trastuzumab deruxtecan (T-DXd) for previously treated metastatic HER2-positive (IHC 3+) solid tumors, along with strategies for proactive monitoring and management of ADC-associated adverse events.=

CME credits: 0.50 Valid until: 29-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/before-the-scalpel-identifying-candidates-for-perioperative-immunotherapy/57086/ This online CME activity uses a patient–clinician dialogue format to explore the evolving role of perioperative immunotherapy in locally advanced head and neck squamous cell carcinoma (HNSCC). Expert commentary and patient-centered discussions address how to identify appropriate candidates based on disease stage, PD-L1 expression, resectability, and overall fitness for multimodality therapy. The program reviews clinical evidence from perioperative studies, with emphasis on implications for integrating immunotherapy into curative-intent care. Practical considerations include surgical timing, multidisciplinary coordination, and management of immune-related adverse events. By illustrating shared decision-making and real-world communication between clinicians and patients, this program offers actionable insights into aligning treatment with patient goals while optimizing care across the perioperative continuum.

CME credits: 0.50 Valid until: 29-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/choosing-the-path-forward-a-real-world-dialogue-on-perioperative-immunotherapy/57089/ This online CME activity uses a patient–clinician dialogue format to explore the evolving role of perioperative immunotherapy in locally advanced head and neck squamous cell carcinoma (HNSCC). Expert commentary and patient-centered discussions address how to identify appropriate candidates based on disease stage, PD-L1 expression, resectability, and overall fitness for multimodality therapy. The program reviews clinical evidence from perioperative studies, with emphasis on implications for integrating immunotherapy into curative-intent care. Practical considerations include surgical timing, multidisciplinary coordination, and management of immune-related adverse events. By illustrating shared decision-making and real-world communication between clinicians and patients, this program offers actionable insights into aligning treatment with patient goals while optimizing care across the perioperative continuum.

CME credits: 0.50 Valid until: 29-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/partnering-through-treatment-preparing-for-immunotherapy-in-the-perioperative-setting/57090/ This online CME activity uses a patient–clinician dialogue format to explore the evolving role of perioperative immunotherapy in locally advanced head and neck squamous cell carcinoma (HNSCC). Expert commentary and patient-centered discussions address how to identify appropriate candidates based on disease stage, PD-L1 expression, resectability, and overall fitness for multimodality therapy. The program reviews clinical evidence from perioperative studies, with emphasis on implications for integrating immunotherapy into curative-intent care. Practical considerations include surgical timing, multidisciplinary coordination, and management of immune-related adverse events. By illustrating shared decision-making and real-world communication between clinicians and patients, this program offers actionable insights into aligning treatment with patient goals while optimizing care across the perioperative continuum.

CME credits: 1.00 Valid until: 29-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/cushing-syndrome-strategies-diagnosis-management/39896/ This webinar aims to give learners a case-based exploration of hypercortisolism/Cushing Syndrome (CS) care, covering screening, diagnosis, referral, and treatment. It will closely examine how to identify and screen for atypical presentations of CS, as well as approaches to managing mild cases. The program will then build on these fundamentals by applying them to real-world treatment scenarios.=

CME credits: 0.50 Valid until: 29-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/turning-evidence-into-action-applying-perioperative-data-to-real-world-practice/57091/ This online CME activity uses a patient–clinician dialogue format to explore the evolving role of perioperative immunotherapy in locally advanced head and neck squamous cell carcinoma (HNSCC). Expert commentary and patient-centered discussions address how to identify appropriate candidates based on disease stage, PD-L1 expression, resectability, and overall fitness for multimodality therapy. The program reviews clinical evidence from perioperative studies, with emphasis on implications for integrating immunotherapy into curative-intent care. Practical considerations include surgical timing, multidisciplinary coordination, and management of immune-related adverse events. By illustrating shared decision-making and real-world communication between clinicians and patients, this program offers actionable insights into aligning treatment with patient goals while optimizing care across the perioperative continuum.

CME credits: 0.50 Valid until: 29-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/all-hands-on-deck-multidisciplinary-coordination-for-smarter-perioperative-care/57093/ This online CME activity uses a patient–clinician dialogue format to explore the evolving role of perioperative immunotherapy in locally advanced head and neck squamous cell carcinoma (HNSCC). Expert commentary and patient-centered discussions address how to identify appropriate candidates based on disease stage, PD-L1 expression, resectability, and overall fitness for multimodality therapy. The program reviews clinical evidence from perioperative studies, with emphasis on implications for integrating immunotherapy into curative-intent care. Practical considerations include surgical timing, multidisciplinary coordination, and management of immune-related adverse events. By illustrating shared decision-making and real-world communication between clinicians and patients, this program offers actionable insights into aligning treatment with patient goals while optimizing care across the perioperative continuum.

CME credits: 0.25 Valid until: 27-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/diagnose-hypercortisolism-cardiometabolic-conditions/50069/ With an updated understanding of how common hypercortisolism is among patients with hard-to-manage cardiometabolic conditions, what are the implications for clinical practice? How can healthcare providers determine who should be screened, carry out straightforward screening, and confirm a diagnosis? And once hypercortisolism is identified, what are the next steps? Join our experts as they walk through a step-by-step approach to screening and diagnosis, followed by a discussion of appropriate next actions.=

CME credits: 0.25 Valid until: 26-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/Making-the-Right-Moves-in-Metastatic-CSPC-Intensification-Imaging-and-Impact/56687/ Drs. Neeraj Agarwal and Rana McKay discuss treatment intensification strategies in metastatic castration-sensitive prostate cancer (mCSPC), with a focus on combining androgen deprivation therapy (ADT) with androgen receptor pathway inhibitors (ARPIs) and chemotherapy. They review key clinical trial data supporting doublet and triplet regimens that improve overall survival and other clinically meaningful outcomes. The faculty examine how disease burden, metastatic pattern, genomic features, comorbidities, and patient fitness inform selection of doublet versus triplet therapy. They also highlight multidisciplinary approaches to managing treatment-related adverse events and preserving quality of life in patients receiving intensified treatment.=

CME credits: 1.00 Valid until: 22-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/il-36-gpp-pathogenesis-therapy/54775/ Generalized pustular psoriasis (GPP) can look familiar but missing it can have serious consequences. Uncover how IL-36 signaling and immune dysregulation shape disease presentation, progression, and treatment response. You'll learn to distinguish GPP from other neutrophilic dermatoses using clinical clues, biomarkers, and diagnostic tools. Explore how emerging targeted therapies are changing what's possible for patients who previously had limited options. Real-world strategies will help you build comprehensive, long-term management plans that go beyond symptom control. If you've ever second-guessed a pustular case, this activity will sharpen your clinical instincts.=

CME credits: 0.25 Valid until: 21-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/translating-the-latest-kdigo-guidelines-into-practice-iv-iron-therapy-in-patients-with-nondialysis-dependent-ckd/54631/ Iron deficiency and iron-deficiency anemia are related but distinct clinical entities, with iron deficiency often preceding or occurring independently of anemia. In chronic kidney disease (CKD), inflammation-driven iron sequestration and impaired iron availability frequently develop before hemoglobin declines, making hemoglobin-only screening insufficient. Recent updates to the KDIGO 2026 Clinical Practice Guideline for the Management of Anemia in CKD highlight the expanded role of IV iron replacement therapy in patients with non–dialysis-dependent CKD, along with the need for proactive iron assessment, earlier identification of iron deficiency phenotypes, and individualized selection of iron replacement strategies to improve long-term patient outcomes. =

CME credits: 0.25 Valid until: 15-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/ibd-in-focus-a-case-based-approach-to-diagnosis-and-assessment/49150/ In this case-based discussion, Drs. Dolinger and Rubin examine the diagnostic approach to patients presenting with signs and symptoms suggestive of inflammatory bowel disease (IBD). The conversation explores key steps in the initial evaluation, appropriate laboratory testing, the role of colonoscopy versus additional noninvasive work-up, and how imaging modalities such as intestinal ultrasound contribute to disease characterization. The faculty also address methods to assess disease severity and activity, incorporating clinical indices, endoscopic findings, and risk stratification.=

CME credits: 0.25 Valid until: 15-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/movements-with-meaning-reading-the-pattern-not-the-label/54715/ This Podcast Plus discussion examines how to distinguish tardive dyskinesia (TD) from other movement disorders using clinical features, medication timing, and response patterns. Key characteristics of TD, including irregular orofacial movements, are compared with drug-induced parkinsonism and akathisia. The discussion highlights the delayed onset of TD following dopamine receptor-blocking agents and compares timing across movement syndromes. It also emphasizes why TD should not be grouped with other extrapyramidal symptoms, as it may be missed, masked, or coexist with other conditions, affecting treatment decisions.=

CME credits: 0.25 Valid until: 15-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/breaking-the-code-mechanisms-and-future-therapies-for-refractory-chronic-cough/50974/ Part of the educational program Bridging Specialties®: Timely Diagnosis and Treatment for Refractory Chronic Cough, this activity explores emerging scientific insights and therapeutic advances shaping the management of refractory chronic cough (RCC). Despite appropriate evaluation and treatment of common etiologies, many patients continue to experience persistent cough consistent with cough hypersensitivity syndrome. Advances in understanding ATP–P2X3 signaling and neural mechanisms have reshaped the conceptual framework for RCC and informed the development of emerging therapies. This activity reviews the neurobiology of cough hypersensitivity, current management gaps, and the evolving therapeutic landscape. Clinicians will gain insight into mechanism-based care strategies and patient-centered counseling considerations in RCC management.=

CME credits: 1.00 Valid until: 15-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/aldosterone-targeted-therapies-uncontrolled-hypertension-chronic-kidney-disease/56405/ Chronic kidney disease (CKD) and high blood pressure (BP) are closely linked and, when not managed appropriately, can lead to serious outcomes such as myocardial infarction, stroke, heart failure, and progression to kidney failure. Pathological excess of aldosterone induces hypertension by forcing the kidneys to excessively retain sodium and water, increasing blood volume, and lowering potassium. Mineralocorticoid receptor antagonists (MRAs), which target the renin-angiotensin-aldosterone system (RAAS), do not fully inhibit the deleterious effects of aldosterone and may increase serum aldosterone concentrations. Highly selective aldosterone synthase inhibitors (ASIs) have emerged as potential alternatives to MRAs; ASIs decrease aldosterone synthesis, providing another strategy to inhibit aldosterone effects without affecting cortisol production.Want to dive deeper into the discussion? Check out Audience Q&A From the Live Symposium in the Related Content section for additional expert insights and practical perspectives on CKD, hypertension, and emerging aldosterone-targeted therapies. =